HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $500
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raised the price target from $462 to $500.
July 19, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on Vertex Pharmaceuticals and raised the price target from $462 to $500.
The raised price target and maintained Buy rating from a reputable analyst firm is likely to positively impact Vertex Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100